Trastuzumab emtansine
- Generic Name
- Trastuzumab emtansine
- Brand Names
- Kadcyla
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1018448-65-1
- Unique Ingredient Identifier
- SE2KH7T06F
- Background
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine deriva...
- Indication
Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
- Associated Conditions
- HER2-Positive Early Stage Breast Cancer, HER2-positive, Metastatic Breast Cancer
- Associated Therapies
- -
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy
- Conditions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 300
- Registration Number
- NCT05754502
- Locations
- 🇮🇹
Nuovo ospedale di Prato - S. Stefano, Prato, Firenze, Italy
🇮🇹IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
🇮🇹A.O.U. Ospedali Riuniti Umberto I, Ancona, Italy
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
- Conditions
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05673928
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 198
- Registration Number
- NCT05650879
- Locations
- 🇺🇸
University of Colorado - Anschutz Medical Campus - PPDS, Aurora, Colorado, United States
🇺🇸Advent Health Orlando, Orlando, Florida, United States
🇺🇸BRCR Medical Center Inc, Plantation, Florida, United States
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05525858
- Locations
- 🇰🇷
Soonchunhyang University Hospital Bucheon, Bucheon, Korea, Republic of
🇰🇷Chungbuk National University Hospital, Chungju, Korea, Republic of
🇰🇷Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Target Recruit Count
- 120
- Registration Number
- NCT05429684
- Locations
- 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳Jin Yang, Xi'an, Shaanxi, China
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 347
- Registration Number
- NCT05415215
- Locations
- 🇧🇦
University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
🇨🇷Clinica CIMCA, San José, Costa Rica
🇵🇪Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica, Arequipa, Peru
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 116
- Registration Number
- NCT05408845
- Locations
- 🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 45
- Registration Number
- NCT05288777
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT04931342
- Locations
- 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1150
- Registration Number
- NCT04873362
- Locations
- 🇺🇸
Alabama Oncology, Alabaster, Alabama, United States
🇺🇸Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center, Burbank, California, United States
🇺🇸Innovation Clinical Research Institute, Cerritos, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.